CSPC to launch Paxlovid version in China; SEC charges ex-Pfizer employee with insider trading

Pfizer inked a deal with a Chinese pharma to launch a form of its Covid-19 antiviral Paxlovid in China.

The company is working with CSPC Pharmaceutical Group, which is based in Shijiazhuang, China, to produce and launch a local brand of the antiviral, according to a news release. Bloomberg reported that Pfizer also has agreements with Meheco to sell the drug in China and Zhejiang Huahai Pharmaceutical to make and distribute it.

CSPC said the partnership aims to improve the accessibility of  theCovid-19 antiviral in China.

CSPC’s stock was up about 2% on Friday.

The SEC announced earlier this week that it brought insider trading charges against Amit Dagar, a former employee at Pfizer, and Atul Bhiwapurkar, his friend and business partner, for trading on the successful Paxlovid trial results that came out at the end of 2021. Pfizer’s stock jumped 11% on Nov. 5, 2021,…
Click here to view original post